These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11678653)

  • 1. Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica.
    Furbacher TR; Gunatilaka AA
    J Nat Prod; 2001 Oct; 64(10):1294-6. PubMed ID: 11678653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity.
    Wada S; Iida A; Tanaka R
    J Nat Prod; 2001 Dec; 64(12):1545-7. PubMed ID: 11754608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triterpenoid constituents isolated from the bark of Abies sachalinensis.
    Wada S; Iida A; Tanaka R
    J Nat Prod; 2002 Nov; 65(11):1657-9. PubMed ID: 12444693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
    Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel DNA topoisomerase inhibitor: dehydroebriconic acid, one of the lanostane-type triterpene acids from Poria cocos.
    Mizushina Y; Akihisa T; Ukiya M; Murakami C; Kuriyama I; Xu X; Yoshida H; Sakaguchi K
    Cancer Sci; 2004 Apr; 95(4):354-60. PubMed ID: 15072595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
    Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
    Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
    Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
    Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
    Han X; Zhong Y; Zhou G; Qi H; Li S; Ding Q; Liu Z; Song Y; Qiao X
    Bioorg Med Chem; 2017 Jun; 25(12):3116-3126. PubMed ID: 28462840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic lanostane-type triterpenoids as inhibitors of DNA topoisomerase II.
    Wada S; Tanaka R
    Bioorg Med Chem Lett; 2005 Jun; 15(12):2966-9. PubMed ID: 15914002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
    Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
    Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical modifications of ergostane-type triterpenoids from Antrodia camphorata and their cytotoxic activities.
    Li B; Kuang Y; Yi Y; Qiao X; Liang L; Ye M
    Bioorg Med Chem Lett; 2021 Jul; 43():128066. PubMed ID: 33915258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity and DNA topoisomerase inhibitory activity of constituents isolated from the fruits of Evodia officinalis.
    Xu ML; Li G; Moon DC; Lee CS; Woo MH; Lee ES; Jahng Y; Chang HW; Lee SH; Son JK
    Arch Pharm Res; 2006 Jul; 29(7):541-7. PubMed ID: 16903072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
    Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGCG regulates the cross-talk between JWA and topoisomerase IIα in non-small-cell lung cancer (NSCLC) cells.
    Li Y; Shen X; Wang X; Li A; Wang P; Jiang P; Zhou J; Feng Q
    Sci Rep; 2015 Jun; 5():11009. PubMed ID: 26046674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha.
    Syrovets T; Büchele B; Gedig E; Slupsky JR; Simmet T
    Mol Pharmacol; 2000 Jul; 58(1):71-81. PubMed ID: 10860928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.